Who Paid My Doc
Thomas Harris
Foot and Ankle Surgery Pasadena, CA Medical Doctor
NPI 1801815428 CMS profile 126650
800 S Raymond Ave, Pasadena, CA 91105
General payments
$3,035,040
Research payments
$0
Ownership & investment interest
$75,129
Through program year 2025, Thomas Harris of Pasadena, CA is reported in the CMS Open Payments database as having received $3,035,040 across 1,303 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $75,129 across 5 holdings.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Foot and Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $452,914 | 171 | |
| 2024 | General | $438,023 | 221 | |
| 2023 | General | $450,820 | 195 | |
| 2022 | General | $391,286 | 179 | |
| 2021 | General | $528,860 | 248 | |
| 2020 | General | $350,000 | 112 | |
| 2019 | General | $423,136 | 177 | |
| 2023 | Ownership | $15,626 | 1 | |
| 2022 | Ownership | $14,674 | 1 | |
| 2021 | Ownership | $14,882 | 1 | |
| 2020 | Ownership | $16,157 | 1 | |
| 2019 | Ownership | $13,790 | 1 |
Beside peers
- Thomas Harris
- Foot and Ankle Surgery median
- Middle half of Foot and Ankle Surgery
- National median
In program year 2025, general payments to Thomas Harris were reported at $452,914. Among 650 Foot and Ankle Surgery profiles paid that year, the median was $1,183 and the middle half received between $267 and $6,309.
Show as a table
| Year | Thomas Harris | Foot and Ankle Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $423,136 | $1,327 | $279–$5,421 | $163 |
| 2020 | $350,000 | $795 | $121–$3,473 | $114 |
| 2021 | $528,860 | $1,289 | $201–$4,963 | $132 |
| 2022 | $391,286 | $1,539 | $270–$6,067 | $149 |
| 2023 | $450,820 | $1,117 | $257–$5,264 | $160 |
| 2024 | $438,023 | $1,064 | $235–$4,944 | $164 |
| 2025 | $452,914 | $1,183 | $267–$6,309 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 13 drugsPart D claims
535
Drug cost
$13,347
Branded share of claims
49%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jublia Efinaconazole | Brand | 11 | $8,093 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 128 | $1,523 | |
| Celecoxib | Generic | 22 | $969 | |
| Gabapentin | Generic | 89 | $849 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 84 | $729 | |
| Pregabalin | Generic | 15 | $426 | |
| Tramadol Hcl | Generic | 72 | $217 | |
| Methylprednisolone | Generic | 28 | $163 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 21 | $155 | |
| Doxycycline Hyclate | Generic | 11 | $102 |
The 10 drugs with the highest cost, of 13 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 168 billing codesPaid by Medicare
$331,591
Medicare patients
685
Services billed
6,716
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 70% | |
| High blood pressure | 68% | |
| Ischemic heart disease | 29% | |
| Diabetes | 26% | |
| Depression | 21% | |
| Osteoporosis | 19% | |
| Cancer | 17% | |
| Chronic kidney disease | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 46 | 74 | $332 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 53 | 2,928 | $289 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 44 | 71 | $56 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,303 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Foot and Ankle Surgery in California
Eric Giza
Foot and Ankle Surgery · Sacramento, CA
Michael Coughlin
Foot and Ankle Surgery · San Francisco, CA
Candice Brady
Foot and Ankle Surgery · Camarillo, CA
Andrew Hsu
Foot and Ankle Surgery · Orange, CA
Eric Tan
Foot and Ankle Surgery · Los Angeles, CA
David Oji
Foot and Ankle Surgery · Los Gatos, CA
Related records
Foot and Ankle Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Foot and Ankle Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.